Short Interest in Revelation Biosciences, Inc. (NASDAQ:REVB) Drops By 87.0%

Revelation Biosciences, Inc. (NASDAQ:REVB) saw a significant decrease in short interest in the month of February. As of February 27th, there was short interest totaling 13,032 shares, a decrease of 87.0% from the February 12th total of 100,079 shares. Currently, 0.2% of the shares of the stock are short sold. Based on an average trading volume of 107,656 shares, the short-interest ratio is currently 0.1 days. Based on an average trading volume of 107,656 shares, the short-interest ratio is currently 0.1 days. Currently, 0.2% of the shares of the stock are short sold.

Institutional Investors Weigh In On Revelation Biosciences

Large investors have recently made changes to their positions in the stock. Armistice Capital LLC increased its holdings in shares of Revelation Biosciences by 442.8% in the fourth quarter. Armistice Capital LLC now owns 434,272 shares of the company’s stock valued at $347,000 after purchasing an additional 354,272 shares during the last quarter. Sabby Management LLC lifted its position in Revelation Biosciences by 192.5% during the fourth quarter. Sabby Management LLC now owns 605,702 shares of the company’s stock worth $484,000 after buying an additional 398,651 shares in the last quarter. Finally, Geode Capital Management LLC acquired a new position in Revelation Biosciences during the fourth quarter worth $27,000. 12.80% of the stock is currently owned by hedge funds and other institutional investors.

Revelation Biosciences Stock Performance

Shares of NASDAQ:REVB traded up $0.06 during midday trading on Tuesday, hitting $1.34. The company’s stock had a trading volume of 95,179 shares, compared to its average volume of 117,251. The company has a market cap of $9.25 million, a P/E ratio of -0.02 and a beta of -0.10. Revelation Biosciences has a 12-month low of $1.19 and a 12-month high of $44.77. The business’s 50 day simple moving average is $2.23 and its 200 day simple moving average is $4.40.

Revelation Biosciences (NASDAQ:REVB) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($1.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.41) by ($0.24). On average, sell-side analysts predict that Revelation Biosciences will post -49.33 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e)” rating on shares of Revelation Biosciences in a research report on Monday, December 22nd. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, Revelation Biosciences has a consensus rating of “Sell”.

Revelation Biosciences Company Profile

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.